Cell and gene therapy experts question where the FDA designation fits in an environment that features a range of intersecting ...

Arsenal Biosciences, a biotech startup based in South San Francisco, is laying off about half of its workers just a year after scoring a $325 million funding round. The cell therapy company is laying ...

For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical meetings in 2025 and 2026. “Interest from clinicians and ...

Each morning for eight weeks, Douley Olivier dragged himself out of bed at 5 a.m. to drop his girlfriend at work so he could drive her car across Dorchester to train as a lab technician in the ...

"Interest from clinicians and patients in the U.S. case series is encouraging,” said Dr. Robert Huizinga, Interim CEO. "revyve products can meaningfully improve outcomes for those suffering from ...

Amgen's new research campus will begin construction this month. (Rendering c/o Amgen) Thousand Oaks-based biotech giant Amgen Inc. announced this month that it plans to invest more than $600 million ...

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

From regulatory reforms to rewarding research and discoveries instead of patient volumes treated at hospitals, the existing ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Cohort 1 and 2, the Phase 2 stage of the KL400-I/II-01 study, evaluate the efficacy and safety of A400/EP0031 90mg orally once daily (QD) for the treatment of patients with pre-treated and ...

Business intelligence firm ThoughtSpot Inc. today announced a fresh batch of features aimed at pushing analytics beyond dashboards and into customers’ applications and workflows. The rollout includes ...

CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged ...